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Introduction
Dysfunction o f  the respiratory muscles frequently 
occurs in patients with severe chronic obstructive 
pulmonary disease (COPD). This is of clinical 
importance since reduced respiratory muscle function 
may contribute to the sensation of dyspnoea, reduced 
exercise capacity, alveolar hypoventilation during 
exercise, nocturnal desaturation, hypercapnia, dysp­
noea sensation and prolonged weaning from 
mechanical ventilation. Indeed, an increased medical 
consumption was observed recently in COPD 
patients with weakness of the respiratory muscles ( 1).
Respiratory muscle dysfunction is caused by 
weakness and/or fatigue of these muscles. Factors 
contributing to the development of respiratory 
muscle dysfunction in COPD include hyperinflation, 
malnutrition, physical inactivity, prolonged use of 
oral corticosteroids, abnormalities in gas exchange 
and electrolyte concentrations, and heart failure. 
Each of these factors may contribute to weakness of 
the respiratory muscles, which in turn pre-disposes to 
fatigue. Hyperinflation causes mechanical disadvan­
tages, increases the work of  breathing and attributes 
to the (already high) energy demands (2). Increased 
energy expenditure may attribute to loss of body 
weight and malnutrition which subsequently may 
reduce muscle mass. These factors in combination 
with metabolic changes and adverse effects of e.g. 
steroid treatment, place the respiratory muscles of 
these patients at risk for fatigue and the subsequent 
development o f  respiratory failure (2 ).
Improvement of respiratory muscle function in 
severe COPD may be expected to reduce dyspnoea 
sensation, increase exercise tolerance, improve gas
* Author to whom correspondence should be addressed at: Depart­
ment of Pulmonary Diseases, University Hospital Nijmegen, 
PO Box 9101, 6500 HB Nijmegen, The Netherlands.
exchange and reduce medical consumption. Several 
approaches to improve respiratory muscle function 
have been explored. These include reduction of 
(increased) respiratory muscle load, specific training 
to improve respiratory muscle strength and endur­
ance, and respiratory muscle rest using mechanical 
ventilatory support (3),
This review will focus on pharmacological inter­
ventions to improve respiratory muscle function 
in patients with COPD. Detailed information will 
be provided on methylxanthines, /?2-adrenoceptor 
agonists (including clenbuterol), scavengers o f  reac­
tive oxygen-derived species, anabolic steroids and 
growth hormone therapy. As for conceptual interest, 
relevant data from healthy subjects and from animal 
experiments will also be discussed.
Methylxanthines
The question whether methylxanthines improve 
respiratory muscle function in humans is a matter of 
ongoing dispute. This review will focus on human 
studies and recent new developments in animal exper­
iments. The studies by Aubier et al. showed that 
theophylline improved respiratory muscle function in 
normal subjects (4) and COPD patients (Table I) 
(5,6). In contrast, other investigators, using different 
protocols in COPD patients, found no effect of  
theophyllines on respiratory muscle function or onset 
o f  fatigue (7-9). The question remains whether a 
beneficial effect o f  methylxanthines on respiratory 
muscle function is the result of direct stimulation 
o f  respiratory muscle contraction (intrinsic effect), 
since a reduction o f  trapped air volume and airway 
resistance was also observed (5,6),
Several recent studies, however, showed beneficial 
effects o f  methylxanthines in respiratory muscle 
dysfunction in specific circumstances, Firstly, in
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Table 1 Respiratory muscle pharmacotherapy in human studies: methylxanthines
Healthy/
COPD Drug, dose, duration, design Result Reference
Healthy Aminophylline i.v., single dose Fresh and fatigued Pcli ~  15% |  after infusion 
(at ~  13 mg 1 “ l)
(4)
COPD Theophylline 13 mg k g - 1  p.o., 
7-30 days (Pl-c)
Fresh Pcli 16% |  at FRC, fatigue J. 
(at — 13 mg 1 “ 1
(5)
COPD Theophylline 10 mg kg ~ 1 p.o., 2 months, PpllPplmi1x |  (at ^  15 mg 1“ ') (6)
(Pl-c, CO)
P im ax -  (at ~  15 mg I “ 1)
i
COPD Aminophylline 12m gkg~* p.o., s.d. 
(Pl-c, CO)
(8)
COPD Theophylline 2*5 mg k g “ 1 i.V., s.d. 
(Pl-c, CO)
Pcli= (at ~ 5 ,  12 and Ì 9 m g l ” 1) (7)
COPD Theophylline p.o., 3 days (Pl-c CO) Fresh and fatigued Pcli= (at — 13 mg 1 ” !) (9)
Healthy Aminophylline 6 mg k g " 1 loading -  
0-9 mg kg -  1 h~  1 (Pl-c)
7V//-snitf and Pcli-twitch |  after ‘exhaustion’, 
at 90% TLC -5 0 -6 0 %  f Pdi\ fresh Pdi=
(at ~  14 mg 1“ ')
( 1 1 )
Healthy Aminophylline 7-6 mg k g ~ 1 i.v. (Pl-c) Pcli-twitch |  (fresh and fatigued); near TLC greater 
effect and prevention of disproportionate decrease 
in fatigue ( ~  two-fold increase in Pili)
(15)
CO, cross-over study design; COPD, chronic obstructive pulmonary disease; FRC, functional residual capacity; 
Pcli, transdiaphragmatic pressure; Pimax, maximal inspiratory mouth pressure; Pl-c, placebo-controlled study design; 
Ppl, pleural pressure; rhGH, recombinant human growth hormone; s.d., single dose; TLC, total lung capacity; increase; 
= , no change; J,, decrease.
anaesthetized dogs, theophylline administration may 
alter respiratory muscle interaction by promoting 
recruitment of the expiratory muscles of the rib cage 
( 10), thus dividing the work of breathing to both 
inspiratory and expiratory muscles. Secondly, an 
interesting observation was made by Wanke et ah 
who reported that, in healthy humans, theophylline 
improved pressure generation at several lung volumes 
(including hyperinflation) in ‘exhausted’ but not in 
‘fresh’ diaphragm (11). Finally, in recent in vivo and 
in vitro animal studies, a beneficial effect of theophyl­
line was found on the foreshortened diaphragm, a 
model of acute hyperinflation, whereas only limited 
effects were found at optimal resting length (12-14). 
In these studies, foreshortened diaphragm twitch 
force (Pt) was increased by ~15%  at a theophylline 
concentration o f  2 0 m g l - 1  (12), At ~ 3 0 m g l ” 1, 
canine transdiaphragmatic pressure (Pcli) was in­
creased by ~57%  at total lung capacity (TLC) (14). 
Similar results were found recently in humans, con- 
finning that aminophylline potentiated diaphragm 
contractility to a greater extent at short fibre lengths 
than at long fibre lengths, under both fresh and 
fatigued conditions (15). Near TLC, aminophylline 
approximately doubled Pcli (at plasma concentration 
12-15 mg 1 “ ’), both before and after fatigue. In con­
clusion, these findings indicate that methylxanthines 
may be o f  clinical importance in patients with 
dynamic hyperinflation and/or diaphragmatic fatigue.
2-Adrenoceptor agonists
SHORT-ACTING /?2-ADRENOCEPTOR AGONISTS
Respiratory muscles, like other skeletal muscles, 
contain /^-adrenergic receptors, predominantly of the 
/?2~subtype. These /?2-adrenoceptors are present both 
in the muscle fibres and in resistance arterioles, 
regulating muscle blood flow (16,17).
The effects of short-acting /?2-adrenoceptor 
agonists on respiratory muscle function have been 
investigated in vivo in anaesthetized dogs (18-21). 
Intravenously administered salbutamol increased 
twitch transdiaphragmatic pressure {Pcli) during 
compensated metabolic acidosis (19). In fatigued 
diaphragm, Pcli was not improved (18,20). However, 
terbutaline, in an i.v. dose of ^25  ¿¿g leg- did 
increase Pcli by 12-20% in fatigued, but not fresh, 
canine diaphragm both after direct and phrenic nerve 
stimulation (2 1 ), Similar findings were reported for
fenoterol (22) and broxaterol (23).
To investigate whether salbutamol has a direct 
effect on rat diaphragm contractile properties, the 
effects of salbutamol were studied strictly in vitro 
and after s.c. administration. Salbutamol increased 
rat contractile properties at low, clinically relevant 
concentrations in fresh diaphragm (24). A possible 
explanation for the lack of effect of /2-agonists on 
fresh diaphragm in the in vivo studies, in contrast to 
the increase in force generation found in vitro, could
!
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Table 2 Respiratory muscle pharmacotherapy in human studies: /^adrenocep to r agonists
H ealthy/
C O P D  Drug, dose, duration, design Result Reference
H ealthy Salbutamol, 4 mg t.i.d. p.o., 3 days (Pl-c) Pdi fresh and fatigued= (27)
H ealthy Salbutamol ~0-05//g  k g '  1 m in “ 1 i.v. (Pl-c) Pimax = , ventilatory endurance= (28)
H ealthy Salbutamol, 8 mg b.i.d. p.o., 14-21 days (Pl-c) Pimax 7 ±  2% |  (14 days) and (30)
15 ± 4 %  t  (21 days)
C O P D Terbutaline, 2*5 mg t.i.d. p.o., 7 days (Pl-c, CO) Pdi=, P im ax= (32)
C O P D Terbutaline, 500-1500/jg q.i.d. inhaled, 7 days Pimax= (33)
(Pl-c, CO)
H ealthy Terbutaline, s.d. 7-5/15 mg p.o. (PI-c) Pimax= (29)
C O P D Broxaterol, 200 jug i.v., single dose (Pl-c) Pimax ~  17% | (34)
C O P D Broxaterol, 0 \5  mg t.i.d. p.o., 7 days (Pl-c, CO) Pimax = , endurance time at 70%Pimax j (35)
H ea lthy Fenoterol, s.d. 5 mg p.o. (Pl-c, CO) Pi//-twitch diaphragm fatigue j, (31)
endurance time at 60%Pimax t
F o r  abbreviations, see Table 1 ,
be that /^-agonists predominantly stimulate type II 
muscle fibre contraction, whereas during normal 
ventilatory manoeuvres in fresh diaphragm, slow 
m otor units are recruited predominantly (25). Type II 
muscle fibres generate higher forces and fatigue more 
easily. In this way, the beneficial effect of /7-agonist 
treatment on fatigued diaphragm could also be 
explained (21-23). In a recent experiment, it was 
found that, similar to the effects o f  methylxanthines, 
the inotropic effect of salbutamol was potentiated by 
foreshortening (26).
The effects of /?2-agonists on diaphragm function in 
healthy humans are contradicting (Table 2 ). Javaheri 
et cd. found no effects of salbutamol on maximal Pdi 
in fresh or fatigued diaphragm after 3 days of oral 
treatment (4 mg t.i.d.) (27). Violante et a l  reported 
that i.v. administration o f  salbutamol had no effect 
on maximal inspiratory mouth pressure (Pimax) and 
ventilatory endurance (28). Also, a single oral dose of 
7-5 or 15 mg terbutaline did not improve Pimax in 
healthy subjects (29). In contrast, Martineau et al. 
reported a significant (7% and 15%) increase in 
Pi-max after, respectively, 14 and 21 days of oral 
salbutamol treatment (8 mg b.i.d.) (30). Recently, 
Suzuki et al. reported that a single 5 mg oral dose of 
fenoterol administered to healthy subjects reduced 
diaphragmatic fatigue and decreased diaphragm 
motor command (measured by EMG); this resulted 
in a reduction of inspiratory effort sensation during 
inspiratory threshold loading and an increase in 
endurance (31).
In COPD patients, oral terbutaline adminis­
tration (32), as well as terbutaline inhalation (33), did 
not improve Pdi (32) or Pimax (32,33). Treatment 
with broxaterol in COPD patients resulted in a
~17% increase in Pimax after i.v. administration 
(200 fig in 10 mill) (34), but no increase in Pimax 
after 7 days of oral treatment (0-5 mg t.i.d.) (35). 
However, this last study did report an increased 
endurance (35).
In contrast to the animal studies, all human studies 
used maximal voluntary contractions. This could 
partly explain the difference in positive effects o f  
^-agonists in fatigued animal in contrast to the 
absence o f  effects in human diaphragm. Further­
more, the human diaphragm has a slightly different 
fibre type composition, but the total amount o f  
oxidative fibres (type I and Ila) is approximately 
equal ( — 70% in rats and — 75% in humans) (36,37). 
Based on these observations, phrenic nerve stimu­
lation seems essential to determine the effects of  
^-adrenoceptor agonists on respiratory muscle func­
tion in both healthy subjects and COPD patients.
LONG-ACTING //2-ADRENOCEPTOR AGONISTS
Data with regard to the respiratory muscles’ effects 
of the new long-acting p2-adrenoceptor agonists 
salmeterol and formoterol in humans are not avail­
able. One study showed that salmeterol had growth 
stimulating effects in rat skeletal muscles (38). This 
effect, however, depended on the route o f  admin­
istration. After oral administration, a growth stimu­
lating effect was found in high salmeterol dosages 
compared to low clenbuterol dosages, whereas 
after s.c. and i.p. administration, saJmeterol and 
clenbuterol had approximately equal effects (38). 
Recently, a preliminary report showed an increase 
in costal diaphragm shortening in canines after 
salmeterol infusion (39).
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CLENBUTEROL
Within the group of /?2-adrenoceptor agonists, 
clenbuterol has a special position. This /?-agonist is 
lipophilic and has a long plasma half-live of elimi­
nation (approximately 30-35 h in humans). Research 
of clenbuterol effects on skeletal muscles mainly 
concentrated on muscle growth enhancement and 
reduction o f  fat deposition.
In peripheral skeletal muscles in normal rats, clen­
buterol increased muscle cell growth and protein 
content in vitro (40) and in vivo (41). These growth 
effects were the result of /?2-adrenoceptor activation 
(42,43) with increased cAMP levels (44). Stimulation 
of skeletal muscle growth and metabolism by clen­
buterol was also found in pathological situations 
including denervation (45,46), tenotomy (47), food 
deprivation (48) and low protein diet (49), In 
mclx mice, a model for (Duchenne) muscular dys­
trophy, clenbuterol increased skeletal muscle mass 
and diaphragm myosin concentration (50,51), and 
increased soleus muscle twitch force (Pt) and 
maximal tetanic force (Po) (52). Long-term treatment 
(1*6 mg k g “ 1 day ~ 1 for 12 weeks) increased Pt and 
Po in soleus (SO), a muscle containing predominantly 
type I muscle fibres, and extensor digitorum longus 
(EDL), containing predominantly type lib  muscle 
fibres (53). However, the increase in force per cross- 
sectional area (CSA) was small (53). Histological 
examination showed hypertrophy of both muscles 
and a 40% increase in type II muscle fibre CSA in SO 
muscle. In EDL type I and II muscle fibres, the CSA 
was increased by 36 and 23%, respectively (53).
Little is known o f  the effect of clenbuterol on 
respiratory muscles. Prezant et al. reported that 
1 mg kg ~ 1 b.i.d. resulted in hypertrophy of both type 
I and type II muscle fibres in rat diaphragm, but force 
generation in fresh diaphragm was reduced in female 
rats, and the fatigue index was reduced in both sexes
(54). The effect of i.v. administered clenbuterol on 
Pdi in dogs was investigated by Numata et a/. (20). 
They found a dose-depending relationship in which 
10 and 2 0 /z g k g ” 1 increased Pdi significantly ( ~ 7 -  
20%) (20). Roth well (42) reported a significant 
(approximately 2 -3 -fold) increase of diaphragm 
blood flow 1 h after administration of 1 mg kg “ 1 s.c. 
in both chronically treated and control groups, but 
no effect o f  chronic clenbuterol treatment on dia­
phragm blood flow. Recently, Rollier et al. reported 
an increase of scalenus, gastrocnemius and SO 
muscle mass in male rats after 2 weeks of clenbuterol 
treatment in addition to inspiratory muscle training
(55). In female rats, only parasternal intercostal mass 
was increased. No effects were found on diaphragm 
contractile properties and fatiguability, but type Ila
muscle fibre CSA was significantly increased in 
female rats, and type lib  fibre CSA was significantly 
increased in both male and female rats (55). 
Clenbuterol treatment also increased diaphragm 
myosin content in mdx  mice, but an increase in 
diaphragm fatiguability was also found after clen­
buterol treatment in both mdx and control mice (51). 
There are no studies of the effect of clenbuterol on 
respiratory muscle function in healthy subjects, nor 
in patients with COPD. In one human study, Maltin 
reported an accelerated increase of quadriceps muscle 
strength after surgery (56).
In conclusion, ^-adrenoceptor agonists could be 
useful in improving respiratory muscle function. 
Especially during fatigue, these agents may increase 
diaphragm contractility, Possibly, clenbuterol might 
be used to increase respiratory muscle mass,
Scavengers of Reactive Oxygen-derived Species
In skeletal muscles, a low level of reactive oxygen 
species (ROS) is essential for excitation-contraction 
coupling and is obligatory for optimal contractile 
function (57). Removal of hydrogen peroxide in fresh 
diaphragm strips using catalase, as well as removal 
o f  superoxide anions using superoxide dismutase 
(SOD), depressed diaphragm twitch force generation 
in vitro (57). This was reversed by addition of 
hydrogen peroxide (57). In fresh rat diaphragm, 
in vitro administration of either the hydroxyl 
scavenger, dimethyl sulphoxide (DMSO) (58), or 
N-acetylcysteine (NAC), which is a precursor of the 
anti-oxidant glutathione (GSH) (59), reduced Pt and 
submaximal tetanic force (58,59),
In case of excessive mechanical loads and fatigue 
of the respiratory muscles, the levels of ROS are 
increased, which may contribute to clinically relevant 
respiratory muscle dysfunction (60). In hamsters, 
several ROS scavengers were used to determine 
the contribution of different ROS in diaphragm 
and intercostal muscle dysfunction in end o toxin - 
mediated sepsis (61). Three scavengers had equal 
beneficial effects: the superoxide scavenger, poly­
ethylene glycol-absorbed superoxide dismutase 
(PEG-SOD); the hydrogen peroxide scavenger, 
PEG-catalase; and the hydroxyl scavenger, DMSO 
(61). SOD, DMSO and catalase also inhibited 
low-frequency, but not high-frequency, fatigue in 
rat diaphragm (62). Pre-treatment with NAC 
(150 mg k g _ l  i.v.) attenuated the rate of fatigue 
development in rabbits (63). Reid et a l  reported that 
NAC, concentration of 10 m M , not only inhibited 
acute fatigue, but also increased in vitro force produc­
tion in fatigued rat diaphragm strips (59). Recovery
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Table 3 Respiratory muscle pharmacotherapy in human studies: anabolic steroids
H eal thy/CO P D Drug, dose, duration, design Result Reference
C O P D Nandrolone decanoate: P/max 19% t  in nutritionally depleted patients, (79)
9 25 mg, ¿  50 mg/2 weeks i.m.. in combination with nutritional support and
for 8 weeks (Pl-c) a rehabilitation programme
F o r  abbreviations, see Table 1.
from  fatigue, however, was not improved (64). 
Recently, Supinski et al. showed that i.v. admin­
istration o f  N A C  (150 mg k g ~ ]) increased dia­
phragm G SH  and oxidized glutathione (GSSG) levels 
in  rats exposed to massive inspiratory loading (65). 
T h is  increased GSH level was accompanied by an 
approximately 60% increase in fatigue resistance 
in vitro, but NAC did not alter the time to respiratory 
arrest during loaded breathing (65). In humans, 
treatment with NAC (150 mg k g - 1  i.v.) attenuated 
the  development o f  fatigue during low-frequency 
electrical stimulation in tibialis anterior muscle, and 
increased force output by ~  15% during fatigue (66). 
Reports on  the effects of reactive oxygen scavengers 
o n  human respiratory muscle (dys-) function are not 
available, except for one preliminary report (67). This 
pilot study reported an attenuating effect of NAC 
infusion on  the development of diaphragm fatigue in 
tw o healthy subjects (67).
In summary, preliminary data suggests that 
lowering increased levels o f  ROS may be of clinical 
importance in critically ill patients and patients with 
overt or incipient respiratory muscle fatigue. Treat­
m ent with ROS scavengers could possibly increase 
respiratory muscle function in these circumstances, 
but this needs to be investigated.
Anabolic Steroids
Little is known of the effects o f  androgens on 
respiratory muscle function. Human studies have 
concentrated on peripheral skeletal muscle strength 
and shown that slight increases in strength are 
predominantly found in previously trained athletes 
taking anabolic steroids (68). In animals, treatment 
with anabolic steroids increased diaphragm muscle 
weight, percentage and relative CSA of type Ila 
muscle fibres, as well as capillary: fibre ratio and 
glycolytic capacity (69,70). Preliminary data in 
rats suggested that administration of nandrolone 
decanoate (1*5 and 7*5 mg k g " ' 1 w eek“ 1 i.m.) did 
not increase respiratory muscle m a ss : body weight 
ratio in female rats, and contractile properties in 
the diaphragm were not altered (71). Also, in
combination with inspiratory muscle training, no 
additive effects o f  nandrolone decanoate were found 
in rats (72). In contrast, a preliminary study using 
dehydroepiandrosterone (D H EA ) reported an ~  24% 
increase in Po in rat diaphragm, whereas fatigue 
index was not changed (73). Furthermore, in male 
hamsters, continuous sx. administration o f  nan­
drolone significantly increased diaphragm isometric 
and isotonic contractile properties, and caused hyper­
trophy of all muscle fibre types, but did not change 
fatigue resistance (74).
Testosterone administration (9-12*5 mg kg“ 1 
day" 1, 5 days w eek “ 1 i.m.) in rats increased dia­
phragm muscle mass and reduced fatigue resistance 
in female but not in male rats (75). Testosterone 
treatment increased diaphragm contractility in 
female rats alone after short-term (2-5 weeks), but 
not after long-term (10 weeks), treatment; no changes 
in fibre type proportion or area were found (75). In 
hamsters, continuous s.c. administration of testoster­
one for 6 weeks increased diaphragm optimal length, 
specific force production and relative contribution of 
type II fibres, but did not change fatigue resistance 
(76). In rabbits, in vivo administration of testosterone 
(20 mg kg“ 1 day" l, 14 days i.m.) reduced the effects 
of concomitant corticosteroid treatment (cortisone 
10 mg kg“ 1 day “ 1 i.m.) on the diaphragm (77). 
Testosterone alone had no effect on  diaphragmatic 
strength (Pdi), endurance or biochemistry, but 
blunted the effects o f  cortisone on diaphragmatic 
endurance (77). In a recent experiment in the authors’ 
laboratory, this effect was confirmed. Concomitant 
administration of nandrolone decanoate completely 
antagonized methylp red ni sol one-induced functional 
changes and partly reversed (immuno-) histochemical 
changes in rat diaphragm (78).
There is little data on the effects of anabolic 
steroids on respiratory muscle function in humans 
(Table 3). Schols et al. reported a significant increase 
( ~  19%) in Pimax in COPD patients with nutritional 
depletion receiving an 8-week treatment o f  nan­
drolone decanoate in combination with supplemental 
nutrition compared to placebo (79). All these patients 
participated in an intensive inpatient rehabilitation
518 Topical Review
Table 4 Respiratory muscle pharmacotherapy in human studies: growth hormone
Healthy/COPD Drug, dose, duration, design Result Reference
COPD rhGH 0-05 mg kg ~ 1 day ~ 1 s.c. Pimax 27 ±  8% in malnourished patients, (87)
for 3 weeks in combination with normally recommended diet
COPD 1 week of s.c. rhGH: 30 /^gday“ 1 Pimax = , in malnourished patients, in combination (88)
(3 days) and 6 0 / ig d ay "  1 (4 days) with total parenteral nutrition scheme
COPD rhGH 0-15 U kg~ 1 day"  1 s.c. Pimax = , in underweight patients, in combination (89)
for 3 weeks (Pl-c) with in-hospital rehabilitation programme
Acute rhGH 0-14 mg kg"  1 day“ 1 s.c. Duration of mechanical ventilatory support = , (90)
respiratory for 12 days (Pl-c) (incritically ill patients with nutritional support)
failure
For abbreviations, see Table 1.
programme, and the majority of these patients had 
concomitant corticosteroid medication.
In conclusion, the studies in normal animals found 
contradicting results and did not show conclusively 
that administration of anabolic agents improves 
respiratory muscle function. However, adminis­
tration of these agents to malnourished, nutritionally 
depleted, COPD patients may increase respiratory 
muscle function. There could be a role for anabolic 
steroids in rebuilding the contractile apparatus but, 
more importantly, these agents may prove useful in 
preventing the deleterious effects of corticosteroids 
on respiratory muscles. This effect appears to be 
based on a competitive binding of androgens and 
corticosteroids to the steroid receptor (80).
Growth Hormone Therapy
Patients with COPD, and particularly those with 
emphysema, are often underweight and malnour­
ished (81-83). This condition is associated with 
increased mortality and morbidity, and a decrease in 
respiratory muscle function (83-86). Often these 
patients are unable to meet their increased nutritional 
demands. Besides dietary supplementation, growth 
hormone therapy may be considered, since this 
therapy has potent anabolic effects and enhances 
protein synthesis.
In a non-controlled study in seven malnourished 
COPD patients (Table 4), human recombinant 
growth hormone in a dose of 0*05 mg kg“ 1 day“ 1 in 
addition to a balanced diet increased Pimax by 
~27%  after 3 weeks of treatment (87). In contrast, 
1 week of growth hormone treatment in addition to a 
2-week parenteral nutrition treatment did not 
increase respiratory muscle function (88). Similarly, 
during a 3-week in-hospital rehabilitation period, 
growth hormone treatment did not increase Pimax 
(89). Finally, in critically ill patients undergoing
prolonged mechanical ventilation, administration 
of growth hormone did not influence the duration of 
ventilatory support (90).
Contradicting results have also been reported 
in studies investigating the effects of nutritional 
repletion alone. Several studies found no effects of 
short-term re-feeding (91) or long-term supplemental 
feeding (92,93) on Pimax in malnourished COPD 
patients, In contrast, another study reported a ~ 35 -  
40% increase in Pimax and Pcli after 3 weeks of 
nutritional repletion (94). Despite these contradic­
tions, nutritional assessment and management is an 
important therapeutic modality that should be con­
sidered in the treatment of COPD patients (81,86).
In animal studies, administration of growth 
hormones did not prevent rat diaphragm fibre 
atrophy after acute nutritional deprivation (95), but 
did reverse the reduction CSA of all fibre types in 
moderate nutritional deprivation (96). Furthermore, 
growth hormone accelerated body growth and pro­
moted a selective hypertrophy of IIx fibres (97). This 
IIx diaphragm fibre hypertrophy, however, was not 
accompanied by an increase in in vitro contractile 
properties (97). Further, in a study investigating the 
recovery from a 25% weight loss after nutritional 
deprivation, growth hormone administration in com­
bination with re-feeding reversed the atrophy found 
in every type II muscle fibres in the rat diaphragm 
(98). In contrast, after re-feeding for 5-9 weeks 
without growth hormone administration, this return 
to control value CSA was only observed in Ila muscle 
fibres and not in type lib or IIx fibres (98).
Growth hormone therapy might also be of value 
to prevent the side-effects of corticosteroid treatment 
on respiratory muscles. Administration of growth 
hormone prevented prednisone-induced protein 
catabolism both in healthy subjects treated with high 
doses of prednisone for 7 days, and in patients with 
chronic prednisone treatment (99,100). In contrast to
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these human data, growth hormone did not prevent 
the histochemical and functional changes in rat dia­
phragm induced by triamcinolone treatment ( 101). 
This may be explained by the fact that triamcinolone 
treatment also reduced nutritional intake, which was 
not corrected ( 10 1 ).
In conclusion, growth hormone therapy may, simi­
lar to anabolic steroids, increase respiratory muscle 
mass and possibly prevent steroid-induced muscle 
wasting. However, the effects on respiratory 
muscle function in COPD patients with respiratory 
muscle weakness is not yet established.
Conclusions and Clinical Implications
In patients with severe COPD, several mechanisms 
impair the respiratory muscle function, whilst the 
workload o f  these muscles is already increased 
and their reserve capacity is reduced. Selective 
pharmacological interventions may be considered in 
the treatment of both acute and chronic respiratory 
muscle dysfunction. Based on the current data, 
several speculative recommendations may be 
formulated.
(1) When acute hyperinflation is the most prominent 
factor reducing respiratory muscle function, 
treatment with methylxanthines would be appro­
priate since, at normal plasma concentrations, 
Pdi was approximately doubled near TLC (15).
(2 ) in case o f  overt or developing respiratory muscle 
fatigue, further cellular damage may be pre­
vented by administering ROS scavengers, Force 
generation could be increased in fatigued muscles 
by /?2~adrenoceptor agonists and reactive oxygen 
scavengers in this acute situation. A Pdi increase 
could be expected of /7-agonist treatment, 
whereas NAC has been shown to increase 
diaphragm fatigue resistance.
(3) Anabolic steroids and growth hormone therapy 
could possibly prevent deleterious effects of  
corticosteroids on respiratory muscles.
(4) The p2~adrenoceptor agonist clenbuterol might 
be useful in the treatment of chronic respiratory 
muscle failure by increasing respiratory muscle 
mass. It is clear, however, that further studies are 
necessary to determine the clinical benefit of these 
approaches.
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